E
Erik Ingelsson
Researcher at Stanford University
Publications - 546
Citations - 99427
Erik Ingelsson is an academic researcher from Stanford University. The author has contributed to research in topics: Genome-wide association study & Population. The author has an hindex of 124, co-authored 538 publications receiving 85407 citations. Previous affiliations of Erik Ingelsson include Karolinska Institutet & Cardiovascular Institute of the South.
Papers
More filters
Journal ArticleDOI
Homogeneity in the association of body mass index with type 2 diabetes across the UK Biobank: A Mendelian randomization study
Michael Wainberg,Anubha Mahajan,Anshul Kundaje,Mark I. McCarthy,Mark I. McCarthy,Erik Ingelsson,Nasa Sinnott-Armstrong,Manuel A. Rivas +7 more
TL;DR: In a population-scale cohort, lower BMI was consistently associated with reduced diabetes risk across BMI, family history, and genetic risk categories, suggesting all individuals can substantially reduce their diabetes risk through weight loss.
Journal ArticleDOI
Rediscovery rate estimation for assessing the validation of significant findings in high-throughput studies
TL;DR: In high-throughput studies, the proportion of significant findings from a 'training' sample that are replicated in a 'validation' sample is a function of false-positive rate and power in both the training and validation samples, which is referred to as rediscovery rate (RDR).
Journal ArticleDOI
Identification of 22 novel loci associated with urinary biomarkers of albumin, sodium, and potassium excretion
Daniela Zanetti,Daniela Zanetti,Abhiram Rao,Stefan Gustafsson,Themistocles L. Assimes,Stephen B. Montgomery,Erik Ingelsson,Erik Ingelsson,Erik Ingelsson +8 more
TL;DR: Overall, 22 novel genome-wide significant associations with urinary biomarkers are identified and several previously established associations are confirmed, providing new insights into the genetic basis of these traits and their connection to chronic diseases.
Journal ArticleDOI
A Nationwide Study of Inpatient Admissions, Mortality, and Costs for Patients with Cirrhosis from 2005 to 2015 in the USA.
Biyao Zou,Yee Hui Yeo,Donghak Jeong,Haesuk Park,Edward Sheen,Dong Hyun Lee,Linda Henry,Gabriel Garcia,Erik Ingelsson,Ramsey Cheung,Ramsey Cheung,Mindie H. Nguyen +11 more
TL;DR: Rates and costs of admissions in cirrhotic patients have increased substantially between 2005 and 2015 in the USA, but varied by liver disease etiology, with decreasing rate for HCV-associated cirrhosis and for HBV- associated cir rhosis but increasing for NAFLD-associated Cirrhosis.
Journal ArticleDOI
Genome-wide association study of coronary artery disease among individuals with diabetes: the UK Biobank
TL;DR: The authors' results indicate large similarities between the genetic architecture of CAD in participants with and without diabetes, and larger studies are needed to establish whether there are important diabetes-specific CAD loci.